Ashwin Kishtagari
YOU?
Author Swipe
View article: Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis Open
Supplemental Tables S1-S9Supplemental Figures S1-S2
View article: Human level information extraction from clinical reports with finetuned language models
Human level information extraction from clinical reports with finetuned language models Open
Extracting structured data from clinical notes remains a key bottleneck in clinical research. We hypothesized that with minimal computational and annotation resources, open-source large language models (LLMs) could create high-quality rese…
View article: Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy
Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy Open
In this cohort study, prior RT was associated with an increased risk of clonal hematopoiesis, particularly among patients receiving higher biologically equivalent radiation doses, stereotactic techniques, or treatment to the spine.
View article: Limited Availability of Variant-Specific Germline Data Creates Challenges in the Interpretation of Myeloid NGS Panels
Limited Availability of Variant-Specific Germline Data Creates Challenges in the Interpretation of Myeloid NGS Panels Open
View article: Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma Open
View article: Supplementary Figure 15 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 15 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 15. Gene expression signatures of stemness and differentiation in the blast compartment of individual patients on UMAP projection.
View article: Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.
View article: Supplementary Table 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 1. Demographics of patients with R/R AML or MDS treated with FHD 286.
View article: Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
View article: Supplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
View article: Supplementary Table 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 4. FHD-286 plasma pharmacokinetic parameters in patients with R/R AML or MDS treated with FHD-286.
View article: Supplementary Figure 12 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 12 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 12: Case 2. Peripheral blast count (top) and absolute neutrophil count (bottom) in a 25-year-old male patient with R/R treatment-related AML with KMT2A rearrangement treated with FHD286 7.5 mg QD.
View article: Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
View article: Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 1. Flow of patients through Study FHD-286-C-002 (monotherapy dose escalation).
View article: Supplementary Data 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Data 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Data_ FHD-286-C-002 study protocol
View article: Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
View article: Supplementary Table 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 5. Characteristics of patients with >50% reduction in bone marrow blasts from baseline.
View article: Supplementary Figure 13 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 13 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 13. Swim lane plot of responses to FHD-286 monotherapy in all patients with AML or MDS (asterisks) who had received ≥1 dose of FHD-286. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; QD, once daily; SD, st…
View article: Supplementary Table 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 3. Baseline disease characteristics of patients with R/R AML or MDS treated with FHD-286.
View article: Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 2. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 33; R/R AML; FHD-286 2.5 mg QD dose group.
View article: Supplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 2: Representativeness of Study Participants.
View article: Data from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Data from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Purpose:Safety and preliminary clinical activity of FHD-286, a dual BRG1/BRM (Brahma related gene 1/Brahma homolog) inhibitor, were evaluated in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.Patients …
View article: Supplementary Figure 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 4. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 7; R/R AML; FHD-286 7.5 mg QD dose group.
View article: Supplementary Figure 11 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 11 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 11. Case 1. Analysis of bone marrow cell morphology with Wright-Giemsa staining in a 47-year-old male patient with complex karyotype treated with FHD-286 10 mg once daily.
View article: Supplementary Figure 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 6. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 18; R/R AML; FHD-286 7.5 mg QD dose group.
View article: Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
View article: Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
View article: Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Open
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
View article: Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control study
Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control study Open
View article: Data from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Data from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants Open
Peripheral nerves promote mouse bone marrow regeneration by activating β2- and β3-adrenergic receptor signaling, raising the possibility that nonselective β-blockers could inhibit engraftment after hematopoietic cell transplants (HCT). We …